Abiopharma

Embecta Corp. Reports Second Quarter Fiscal 2025 Financial Results

Riverstone Holdings Limited - Announcement

Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025

Amphastar Pharmaceuticals to Present at the 2025 Bank of America Health Care Conference

embecta Announces Quarterly Cash Dividend

Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Vir Biotechnology - Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

RadNet, Inc. to Present at the Bank of America Securities 2025 Healthcare Conference on May 13th, 2025

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

Viatris Inc. Class Action: Levi & Korsinsky Reminds Viatris Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 - VTRS